Cargando…
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling weakness through a compromise of neuromuscular transmission. The disease fulfills strict criteria of an antibody-mediated disease. Close to 90% of patients have antibodies directed towards the nicotinic acetylcho...
Autores principales: | Alabbad, Sawsan, AlGaeed, Mohanad, Sikorski, Patricia, Kaminski, Henry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484611/ https://www.ncbi.nlm.nih.gov/pubmed/32915379 http://dx.doi.org/10.1007/s40259-020-00443-w |
Ejemplares similares
-
Serum metabolomics of treatment response in myasthenia gravis
por: Sikorski, Patricia, et al.
Publicado: (2023) -
Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020) -
Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022) -
COVID-19: Neurology residents’ perspective
por: AlGaeed, Mohanad, et al.
Publicado: (2020) -
MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)